🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

73 results for “S.L” Clear

  1. Acetaminophen

    S.L

    Patency of the Ductus Arteriosus

    phase 3 small molecule completed

    1 trial

  2. CBP-201

    S.L

    Atopic Dermatitis

    phase 3 small molecule active

    2 trials

  3. Levetiracetam XR, Masked Keppra® placebo film-coated tablets (a placebo tablet inside a capsule), Keppra 500 mg film-coated tablets, Levetiracetam prolonged-release placebo granules

    Neuraxpharm Pharmaceuticals S.L.

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial

  4. Pred Forte 10 mg/ml colirio en suspensión, Clobetasol propionate ophthalmic nanoemulsion, 0.05%

    Laboratorios Tillomed Spain S.L.U

    Inflammation and pain associated with ocular surgery

    phase 3 small molecule active

    1 trial

  5. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  6. AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

    Minoryx Therapeutics S.L.

    CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)

    phase 2 other active

    1 trial

  7. CBP-201

    S.L

    Moderate-to-severe Atopic Dermatitis

    phase 2 small molecule completed

    2 trials

  8. CBP-201

    S.L

    Chronic Rhinosinusitis With Nasal Polyps

    phase 2 small molecule terminated

    1 trial

  9. CBP-201

    S.L

    Moderate to Severe Persistent Asthma

    phase 2 small molecule completed

    1 trial

  10. Double-Blind 0.2mg CBP-307

    S.L

    Moderate to Severe Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  11. Rademikibart in prefilled syringe

    S.L

    COPD Acute Exacerbation

    phase 2 other active

    1 trial

  12. Rademikibart in prefilled syringe

    S.L

    Asthma Acute

    phase 2 other active

    1 trial

  13. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  14. umbilical cord blood (hUCB) cells

    S.L

    Cerebral Palsy

    phase 2 mab completed

    1 trial

  15. A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

    Laboratorios Tillomed Spain S.L.U

    Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps

    phase 1 other active

    1 trial

  16. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    Neuraxpharm Pharmaceuticals S.L.

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  17. An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device

    Laboratorios Tillomed Spain S.L.U

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  18. Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Diabetes

    phase 1 other active

    1 trial

  19. Bioequivalence clinical trial of two formulations of linagliptin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  20. Bioequivalence clinical trial of two formulations of bilastine.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  21. Bioequivalence clinical trial of two formulations of canagliflozin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  22. Bioequivalence clinical trial of two formulations of dapagliflozin.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  23. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  24. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources